Welcome to LookChem.com Sign In|Join Free
  • or
3-((3,4-difluorophenyl)sulfonyl)-7-fluoro-4-(4-fluorophenyl)quinoline is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1093734-92-9

Post Buying Request

1093734-92-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1093734-92-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1093734-92-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,3,7,3 and 4 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1093734-92:
(9*1)+(8*0)+(7*9)+(6*3)+(5*7)+(4*3)+(3*4)+(2*9)+(1*2)=169
169 % 10 = 9
So 1093734-92-9 is a valid CAS Registry Number.

1093734-92-9Downstream Products

1093734-92-9Relevant academic research and scientific papers

Discovery and Preclinical Characterization of 3-((4-(4-Chlorophenyl)-7-fluoroquinoline-3-yl)sulfonyl)benzonitrile, a Novel Non-acetylenic Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator for Psychiatric Indications

Galambos, János,Bielik, Attila,Krasavin, Mikhail,Orgován, Zoltán,Domány, Gy?rgy,Nógrádi, Katalin,Wágner, Gábor,Balogh, Gy?rgy T.,Béni, Zoltán,Kóti, János,Szakács, Zoltán,Bobok, Amrita,Kolok, Sándor,Mikó-Bakk, Mónika L.,Vastag, Mónika,Sághy, Katalin,Laszy, Judit,Halász, Attila Sándor,Balázs, Ottilia,Gál, Krisztina,Greiner, István,Szombathelyi, Zsolt,Keser?, Gy?rgy M.

, p. 2470 - 2484 (2017/04/03)

Negative allosteric modulators (NAM) of metabotropic glutamate receptor 5 (mGluR5) have been implicated as a potential pharmacotherapy for a number of psychiatric diseases, including anxiety and depression. Most of the mGluR5 NAM clinical candidates can be characterized by the central acetylenic moiety that connects the terminal pharmacophores. Identification of a sulfoquinoline hit via high throughput screening (HTS) followed by optimization provided a 4-phenyl-3-aryl-sulfoquinoline lead compound with the minimal pharmacophore. Optimization of the core and aryl appendages was performed by scanning and matrix libraries synthesized by the multiple parallel synthesis approach. Biological evaluation of matrix libraries provided a number of potent, metabolically stable, and in vivo active compounds. One of these compounds, 25 showed high efficacy and safety in preclinical in vivo models; this allowed its nomination as a novel, nonacetylenic mGluR5 NAM clinical candidate. Compound 25 was advanced to first-in-man trials for the treatment of psychiatric conditions.

SULFONYL-QUINOLINE DERIVATIVES

-

Page/Page column 31-32, (2009/01/23)

New mGluRl and mGluR5 receptor subtype preferring ligands of formula: (I) and/or salts and/or hydrates and/or solvates thereof, to the processes and intermediates for their preparation, to pharmaceutical compositions containing these compounds and to thei

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1093734-92-9